Literature DB >> 3516077

Early administration of indomethacin to preterm infants.

J M Rennie, J Doyle, R W Cooke.   

Abstract

Indomethacin (0.2 mg/kg) or saline was given intravenously during the first 24 hours to 50 preterm infants in a double blind controlled trial. Eight of the control group later required treatment with indomethacin for clinical signs of left to right shunt, but only one in the treatment group (p = 0.03). Treatment with indomethacin prolonged bleeding time, raised serum creatinine concentrations, and was associated with gastrointestinal haemorrhage in seven infants. Five of these had a serum indomethacin concentration greater than 1.0 microgram/ml. There was a significant reduction of the stable metabolite of prostacyclin, 6-ketoprostaglandin F1 alpha, commencing six hours after treatment and lasting for four days. There was no significant difference in the incidence of intraventricular haemorrhage, days of treatment with oxygen or ventilation, or mortality between the two groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516077      PMCID: PMC1777724          DOI: 10.1136/adc.61.3.233

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  27 in total

1.  Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome.

Authors:  H W Seyberth; H Müller; L Wille; H Plückthun; D Wolf; H E Ulmer
Journal:  Pediatr Pharmacol (New York)       Date:  1982

2.  A comparison of the abilities of acetylsalicylic acid, flurbiprofen and indomethacin to inhibit the release reaction and prostaglandin synthesis in human blood platelets.

Authors:  S R Cockbill; S Heptinstall; P M Taylor
Journal:  Br J Pharmacol       Date:  1979-09       Impact factor: 8.739

3.  Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis.

Authors:  M A Heymann; A M Rudolph; N H Silverman
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

4.  Pharmacologic closure of patent ductus arteriosus in the premature infant.

Authors:  W F Friedman; M J Hirschklau; M P Printz; P T Pitlick; S E Kirkpatrick
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

5.  Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man.

Authors:  A Rane; O Oelz; J C Frolich; H W Seyberth; B J Sweetman; J T Watson; G R Wilkinson; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

6.  PGE2 is a more potent vasodilator of the lamb ductus arteriosus than is either PGI2 or 6 keto PGF1alpha.

Authors:  R I Clyman; F Mauray; C Roman; A M Rudolph
Journal:  Prostaglandins       Date:  1978-08

7.  Indomethacin therapy on the first day of life in infants with very low birth weight.

Authors:  L Mahony; R L Caldwell; D A Girod; R A Hurwitz; R D Jansen; J A Lemons; R L Schreiner
Journal:  J Pediatr       Date:  1985-05       Impact factor: 4.406

8.  Plasma-prostaglandins in pre-term neonates before and after treatment for patient ductus arteriosus.

Authors:  A Lucas; M D Mitchell
Journal:  Lancet       Date:  1978-07-15       Impact factor: 79.321

9.  Prostaglandins, ductus arteriosus, pulmonary circulation: current concepts and clinical potential.

Authors:  F Coceani; P M Olley; J E Lock
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

10.  The 6-ketoprostaglandin F1alpha pathway in the lamb ductus arteriousus.

Authors:  C R Pace-Asciak; G Rangaraj
Journal:  Biochim Biophys Acta       Date:  1977-03-25
View more
  19 in total

Review 1.  Patent ductus arteriousus in the premature neonate: current concepts in pharmacological management.

Authors:  C Hammerman; M Kaplan
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Effects of ethamsylate on cerebral blood flow velocity in premature babies.

Authors:  J M Rennie; P K Lam
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

3.  Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity.

Authors:  J M Rennie; R W Cooke
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

Review 4.  Prophylactic indomethacin: systematic review and meta-analysis.

Authors:  P W Fowlie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-03       Impact factor: 5.747

5.  Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.

Authors:  Gozde Kanmaz; Omer Erdeve; Fuat Emre Canpolat; Serife Suna Oğuz; Nurdan Uras; Nahide Altug; Ben Greijdanus; Uğur Dilmen
Journal:  Eur J Clin Pharmacol       Date:  2012-11-06       Impact factor: 2.953

6.  Pharmacological manipulation of the ductus arteriosus.

Authors:  E D Silove
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

Review 7.  The pharmacological treatment of patent ductus arteriosus. A review of the evidence.

Authors:  R J Barst; W M Gersony
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 8.  Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.

Authors:  Peter W Fowlie; Peter G Davis; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

9.  Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates.

Authors:  P Colditz; D Murphy; P Rolfe; A R Wilkinson
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

Review 10.  Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis.

Authors:  P W Fowlie; P G Davis
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.